TY - JOUR
T1 - Oral Treatment of Glucocorticoid-Induced Diabetes Mellitus
T2 - A Systematic Review
AU - Klarskov, Carina Kirstine
AU - Holm Schultz, Helga
AU - Wilbek Fabricius, Therese
AU - Persson, Frederik
AU - Pedersen-Bjergaard, Ulrik
AU - Lommer Kristensen, Peter
N1 - This article is protected by copyright. All rights reserved.
PY - 2020/8
Y1 - 2020/8
N2 - Glucocorticoid-induced diabetes mellitus (GIDM) is a well-known and common metabolic side effect of glucocorticoid (GC) treatment. The risk of developing GIDM in non-diabetic patients who receive systemic GCs, was evaluated in a metanalysis and found to be 18.6%. GIDM is potential life-threatening, and hyperglycaemia, even mild, in hospitalized patients is associated with both increased mortality and increased morbidity. Often, insulin is the preferred treatment option. However, insulin is a high-risk drug and to patients without previously known diabetes, initiation of insulin therapy requires training in blood glucose measurements and insulin injections.
AB - Glucocorticoid-induced diabetes mellitus (GIDM) is a well-known and common metabolic side effect of glucocorticoid (GC) treatment. The risk of developing GIDM in non-diabetic patients who receive systemic GCs, was evaluated in a metanalysis and found to be 18.6%. GIDM is potential life-threatening, and hyperglycaemia, even mild, in hospitalized patients is associated with both increased mortality and increased morbidity. Often, insulin is the preferred treatment option. However, insulin is a high-risk drug and to patients without previously known diabetes, initiation of insulin therapy requires training in blood glucose measurements and insulin injections.
UR - http://www.scopus.com/inward/record.url?scp=85088320971&partnerID=8YFLogxK
U2 - 10.1111/ijcp.13529
DO - 10.1111/ijcp.13529
M3 - Letter
C2 - 32392375
SN - 1368-5031
VL - 74
JO - International Journal of Clinical Practice
JF - International Journal of Clinical Practice
IS - 8
M1 - e13529
ER -